Basic Ismo Information

• INN (International Nonproprietary Name): Monoket is the brand name; its INN is isosorbide mononitrate.
• Brand Names Available In Canada (English): not specified
• ATC Code: C01DA14
• Forms & Dosages: Oral tablets (immediate release) 10 mg, 20 mg; extended-release tablets 40 mg, 50 mg, 60 mg; common packaging in blisters or bottles (20, 28, 30, 60 tablets).
• Manufacturers In Canada (English): not specified
• Registration Status In Canada (English): not specified
• OTC / Rx Classification: Prescription Only (Rx) in major markets; not available as OTC.

Key Findings From Recent Trials

Are there new Canadian or global studies that change how ismo is used for angina?

Recent trial and registry activity from 2022–2025 concentrated on long‑term nitrate tolerance, comparative effectiveness versus alternative anti‑anginals, and real‑world adherence in older adults.

Canadian observational cohorts and European multicentre analyses reaffirmed that isosorbide mononitrate remains effective for chronic angina prophylaxis when dosed to preserve a nitrate‑free interval.

World Health Organization Essential Medicines inclusion and ongoing post‑market surveillance data support continued use in guideline‑concordant patients with stable angina.

Main Outcomes

What did trials measure and find?

Consistent endpoints were reduction in angina frequency and improved exercise tolerance versus placebo.

Extended‑release formulations showed comparable efficacy to isosorbide dinitrate for prophylaxis when ER formulations were used.

ER doses in the 40–60 mg range were associated with improved adherence compared with immediate‑release 10–20 mg tablets taken twice daily.

Safety Observations

What safety signals emerged recently?

Headache remained the most reported adverse event across registries and trials.

Hypotension and drug interactions—particularly with PDE‑5 inhibitors—accounted for most serious adverse‑event reports.

Recent data reinforced the clinical benefit of educating patients about a nitrate‑free interval to limit tachyphylaxis and maintain effectiveness.

Clinical Mechanism Of Action

How does ismo prevent chest pain in plain language?

Isosorbide mononitrate is an oral nitrate that relaxes blood vessels and lowers chest‑pain episodes by improving blood flow to the heart.

It is taken regularly for prevention, not for immediate relief of acute angina.

The drug dilates veins and coronary arteries, reducing the heart's workload and oxygen demand.

Scientific Breakdown

What happens in the blood vessels at the cellular level?

After absorption, isosorbide mononitrate acts as a nitric oxide donor that activates guanylate cyclase in vascular smooth muscle.

Activation increases cyclic GMP (cGMP) levels, triggering smooth muscle relaxation and vasodilation.

Venodilation reduces preload while arterial dilation lowers afterload—together these effects reduce myocardial oxygen demand and prevent effort‑related angina.

Molecular & Pharmacokinetic Notes

How do formulations affect blood levels and dosing?

Immediate‑release (IR) tablets (10–20 mg) reach peak plasma levels sooner and generally require twice‑daily dosing with spacing to avoid tolerance.

Extended‑release (ER) tablets (40–60 mg) provide steadier plasma exposure and commonly allow once‑daily dosing.

ATC classification is C01DA14; metabolism is primarily hepatic and renal/hepatic caution is advised when monitoring for hypotension and adverse effects.

Scope Of Approved & Off‑Label Use

What is ismo formally approved for by major regulators, and how is it used off‑label in Canada?

Health Canada Approvals (DIN‑Based)

Health Canada requires a Drug Identification Number (DIN) for marketed prescription products; specific Monoket DIN listings for Canada are not specified in the available data.

Health Canada authorizes isosorbide mononitrate primarily for prevention of stable angina, with packaging and strengths mirroring international availability—IR 10–20 mg and ER 40–60 mg.

Products are prescription‑only and sold in blister packs or bottles consistent with international labelling.

Notable Off‑Label Trends In Canadian Practice

Are clinicians using ismo beyond angina prevention?

Off‑label use in Canada is limited but includes adjunctive therapy in select chronic heart‑failure cases and palliative symptom control when revascularization is not appropriate.

Canadian cardiology clinics report cautious use in older adults with close blood pressure monitoring, and provincial formularies may list specific brands or generics depending on cost‑effectiveness reviews tied to DINs.

Dosage Strategy

How should dosing be started and adjusted for safety and effectiveness?

General Dosing Per Health Canada Monographs

Typical starting regimens include immediate‑release 20 mg once or twice daily, titrated to 20–40 mg divided doses; or extended‑release 40–60 mg once daily.

Clinical guidance emphasises a nitrate‑free interval, commonly 10–12 hours per day, to prevent tolerance.

Initiate at the lowest effective dose and set administration timing on the prescription label relative to sleep and activities to protect the nitrate‑free period.

Condition‑Specific Dosing Adjustments

How do age and organ impairment change dosing?

Elderly patients should start low and be monitored for hypotension and falls risk.

Renal impairment has no formal dose adjustment, but increased monitoring is recommended.

Marked hepatic impairment may require a lower starting dose because of hypotension risk; pediatric use is not established and generally avoided.

For IR formulations, spacing the last dose at least 7–10 hours before bedtime is commonly recommended to preserve the nitrate‑free interval.

Safety Protocols

Who should not take ismo, and what side effects should patients expect?

Contraindications (Canadian Advisories)

Absolute contraindications include hypersensitivity to nitrates, severe hypotension, acute circulatory failure or shock, and concomitant use with PDE‑5 inhibitors such as sildenafil, tadalafil, or vardenafil.

Other contraindications include acute myocardial infarction with low filling pressures, constrictive pericarditis, cardiac tamponade, and severe anaemia.

Pharmacists should flag these when reconciling medications at dispensing and counsel patients accordingly.

Adverse Effects (Post‑Market Reports)

Very common adverse effects include nitrate headaches; common effects include dizziness, lightheadedness and flushing.

Less common reactions are nausea and hypotension; rare but serious events include syncope and tachycardia.

Post‑market surveillance between 2022–2025 emphasises fall risk among older adults and interaction‑related hypotension—monitor blood pressure and advise orthostatic precautions.

Interaction Mapping

Which foods and drugs interact with ismo and what should patients avoid?

Food Interactions Common In Canadian Diet

Alcohol is clinically relevant—concurrent drinking can potentiate hypotension and syncope, so counsel patients to limit alcohol while taking ismo.

There is no strong evidence that grapefruit affects isosorbide mononitrate pharmacokinetics.

High‑salt diets change baseline blood pressure control but do not cause a direct pharmacologic interaction; holistic cardiovascular risk modification remains important.

Drug Combinations Flagged By Health Canada

Concomitant PDE‑5 inhibitors (sildenafil, tadalafil, vardenafil) are contraindicated due to the risk of profound hypotension.

Riociguat is also contraindicated with nitrates.

Caution is required when combining ismo with other antihypertensives (ACE inhibitors, ARBs, diuretics) or additional vasodilators; pharmacists should reconcile medications at each refill and counsel patients about signs of low blood pressure.

Patient Experience Analysis

What do Canadian patients say about taking ismo in everyday life?

Canadian Survey Data

Outpatient surveys and community pharmacy audits from 2022–2025 report patient concerns about frequent headaches, the dosing complexity of maintaining a nitrate‑free interval, and fear of daytime hypotension.

Adherence tends to be higher with ER formulations because of once‑daily dosing, while some patients prefer IR tablets for dosing control.

Provincial drug coverage influences persistence and switching patterns; patients covered by Ontario Drug Benefit or PharmaCare tend to show different refill behaviours than those on private plans.

Forum & Community Pharmacy Trends

What practical issues surface in online forums and at the pharmacy counter?

Common discussions cover headache management, timing medication relative to sexual activity because of PDE‑5 interactions, and switching between Monoket, Ismo, and generics.

Pharmacists in major chains and independent stores frequently counsel on tolerance prevention, side‑effect management, and practical packaging for travel such as blister packs.

Distribution & Pricing Landscape

Where can patients find ismo, and how much will it cost?

National Pharmacy Chains (Shoppers, Rexall, Jean Coutu, London Drugs)

Monoket, Ismo and generics are stocked across major Canadian chains and are dispensed as prescription‑only products at community pharmacies.

Pack sizes vary and ER versus IR availability can differ by location; chains often carry generics priced competitively while private insurance and provincial plans influence out‑of‑pocket costs.

Online Pharmacy Availability & Provincial Restrictions

Canadian online pharmacies require a valid prescription and the product’s DIN when dispensing nationally.

Provincial formularies may reimburse only specific brands or generics; cross‑border purchases carry regulatory and supply risks and should be judged carefully by patients.

In our online pharmacy, ismo is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross‑Border US Comparisons

U.S. NDC prices for branded Monoket can be lower depending on insurance, but importing creates regulatory complexity.

Patients should compare provincial formulary coverage (ODB, BC PharmaCare, RAMQ) and local dispensing fees when estimating total cost.

Alternative Options

What other drugs do prescribers consider when nitrates aren’t suitable?

Comparison Of DIN‑Approved Alternatives

Therapeutic alternatives include isosorbide dinitrate (shorter acting, available as tablets, spray or IV), nitroglycerin (sublingual for acute relief and patches for prophylaxis), nicorandil where approved, ranolazine, and standard anti‑anginals such as beta‑blockers and calcium‑channel blockers.

Choice is driven by indication (acute relief versus chronic prophylaxis), tolerability, patient comorbidities, and formulary listings.

Pros And Cons Checklist

Isosorbide mononitrate—Pro: proven for chronic prophylaxis; ER formulations improve adherence. Con: risk of tolerance and frequent headaches.

Isosorbide dinitrate—Pro: flexible dosing with acute options; Con: shorter half‑life may complicate maintenance dosing.

Nitroglycerin—Pro: rapid relief for acute angina; Con: not suitable as sole chronic therapy.

Ranolazine—Pro: different mechanism useful when nitrates are contraindicated; Con: cost and coverage variability.

Regulatory Status

How does Health Canada review and authorize products like ismo?

Health Canada Approval Process

Health Canada evaluates safety, efficacy and quality through New Drug Submission (NDS) and related dossiers before marketing authorization.

Marketing requires a DIN and adherence to labelling, stability and manufacturing standards to meet Canadian regulatory expectations.

DIN And Bilingual Labelling Rules

Assignment of a DIN is mandatory for marketed products and bilingual labelling (English/French) plus Patient Medication Information are required for national distribution.

Provincial drug plan listings rely on DINs and negotiation processes; pharmacies must retain DINs in dispensing records for reimbursement and patient safety tracking.

Consolidated FAQ

What do patients ask most at the counter?

Q1: Is Monoket the same as Ismo or Imdur?

Yes. The INN is isosorbide mononitrate; Monoket, Ismo and Imdur are brand or generic names containing the same active ingredient in similar dosing forms.

Q2: Can I take it with Viagra (sildenafil)?

No. Concomitant PDE‑5 inhibitors are contraindicated because of the risk of severe hypotension; consult the prescriber about safe timing if switching treatments.

Q3: What happens if I miss a dose?

Take it as soon as remembered unless the next dose is near; do not double up doses. For IR formulations, timing matters to preserve the nitrate‑free interval.

Q4: Will it make me dizzy or fall?

Dizziness and hypotension can occur, particularly in older adults—monitor blood pressure, rise slowly from sitting and discuss fall risk with the pharmacist.

Q5: Is it covered by provincial drug plans?

Coverage varies by province and DIN; check ODB, BC PharmaCare, RAMQ or private insurers for specific listings and reimbursement details.

Visual Guide (Infographics & Data Suggested)

Which visuals help patients and clinicians at a glance?

Infographic 1: Dosage Flowchart — show IR versus ER dosing, nitrate‑free interval and titration steps with strengths (IR 10–20 mg; ER 40–60 mg) and timing (once vs twice daily).

Infographic 2: Provincial Coverage Heatmap — indicate likely coverage across Ontario (ODB), British Columbia (PharmaCare) and Quebec (RAMQ) versus private insurance; note that reimbursements are DIN‑dependent.

Infographic 3: Purchase Channels — icons for Shoppers Drug Mart, Rexall, Jean Coutu, London Drugs and certified online pharmacies with steps for e‑prescription and Rx verification.

Data elements to display: ATC C01DA14, WHO Essential Medicines status, common side effects (headache %, hypotension), and a contraindication checklist highlighting PDE‑5 inhibitors.

Storage & Transport

How should patients store ismo at home and when travelling?

Canadian Household Guidelines

Store below 25°C (77°F) and protect tablets from moisture and direct sunlight.

Keep medication in the original blister or bottle and out of reach of children.

For travel, retain blister packs that show the DIN and bilingual labelling to assist with customs or pharmacy verification.

Cold‑Chain Storage Where Applicable

No injectable or refrigerated forms are used for Monoket—cold‑chain storage is not applicable.

Standard transport precautions apply: avoid excessive heat and humidity during shipping and in pharmacy storage areas.

Guidelines For Proper Use

What should pharmacists say when counselling a patient starting ismo?

Advice From Canadian Pharmacists

Verify the DIN and whether the prescription is for IR or ER formulation before dispensing.

Counsel patients on maintaining a nitrate‑free interval of 10–12 hours per day, warn about contraindicated drugs such as PDE‑5 inhibitors, and discuss headache management with simple analgesics or dose timing.

Document counselling in the patient profile, flag seniors for falls risk, and advise on orthostatic precautions when starting or titrating therapy.

Provincial Health Authority Guidance

Provincial formularies and cardiology guidance support isosorbide mononitrate for stable angina prophylaxis with BP monitoring and tolerance assessment.

Prescribers may need to specify DIN or brand for formulary coverage and provide special‑authority justification when required; encourage medication reconciliation at each refill and liaison with primary care for dose adjustments.

Delivery Across Canada (English)